Trevi Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026More shares for employee compensation lets the company attract talent without using cash immediately.
Quarterly earnings show whether the company is progressing toward its goals or burning cash faster.
Money raised helps the company complete drug trials and runway gives visibility into how long it can operate.
New shares being offered means existing owners' stakes get diluted but company raises cash to fund operations.
Company locked in sale price for new shares and expects cash through 2029 for Haduvio drug development.
New shares being offered means existing owners' stakes get diluted but company raises cash to fund operations.
Full-year results show total revenue, expenses and cash position to evaluate company financial health.
Stocky reads Trevi Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Trevi Therapeutics, Inc.'s most recent tracked filing was a 8-K on 4 Jun 2026: Stockholders approve stock plan expansion by 8 million shares.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.